Northpond Ventures Form 3 DICE Therapeutics / Michael P. Rubin ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Northpond Ventures GP, LLC

(Last)

(First)

(Middle)

7500 OLD GEORGETOWN ROAD, SUITE 850

(Street)

BETHESDA

20814

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/14/2021

3. Issuer Name and Ticker or Trading Symbol
DICE Therapeutics, Inc. [ DICE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Convertible Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	1,735,388	⁽¹⁾	I	By: Northpond Ventures, LP⁽⁴⁾
Series C Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	867,687	⁽²⁾	I	By: Northpond Ventures, LP⁽⁴⁾
Series C-1 Convertible Preferred Stock	⁽³⁾	⁽³⁾	Common Stock	454,796	⁽³⁾	I	By: Northpond Ventures II, LP⁽⁵⁾

1. Name and Address of Reporting Person^*

Northpond Ventures GP, LLC

(Last)

(First)

(Middle)

7500 OLD GEORGETOWN ROAD, SUITE 850

(Street)

BETHESDA

20814

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Northpond Ventures, LP

(Last)

(First)

(Middle)

7500 OLD GEORGETOWN ROAD, SUITE 850

(Street)

BETHESDA

20814

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Northpond Ventures GP II, LLC

(Last)

(First)

(Middle)

7500 OLD GEORGETOWN ROAD, SUITE 850

(Street)

BETHESDA

20814

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Northpond Ventures II, LP

(Last)

(First)

(Middle)

7500 OLD GEORGETOWN ROAD, SUITE 850

(Street)

BETHESDA

20814

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Rubin Michael P.

(Last)

(First)

(Middle)

7500 OLD GEORGETOWN ROAD, SUITE 850

(Street)

BETHESDA

20814

(City)

(State)

(Zip)

Explanation of Responses:

1. All shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Series B Convertible Preferred Stock"), of DICE Therapeutics, Inc. (the "Issuer") will automatically convert on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. The Series B Convertible Preferred Stock has no expiration date.

2. All shares of Series C Convertible Preferred Stock, par value $0.0001 per share (the "Series C Convertible Preferred Stock"), of the "Issuer will automatically convert on a one-for-one basis into shares of the Issuer's Common Stock prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Preferred Stock has no expiration date.

3. All shares of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the "Series C-1 Convertible Preferred Stock"), of the "Issuer will automatically convert on a one-for-one basis into shares of the Issuer's Common Stock prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C-1 Preferred Stock has no expiration date.

4. Northpond Ventures GP, LLC ("Northpond GP LLC") is the general partner of Northpond Ventures, LP ("Northpond Fund"), and Michael P. Rubin is the managing member of Northpond GP LLC. As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

5. Northpond Ventures GP II, LLC ("Northpond GP II LLC") is the general partner of Northpond Ventures II, LP ("Northpond Fund II"), and Michael P. Rubin is the managing member of Northpond GP II LLC. As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

Remarks:

	Northpond Ventures GP, LLC By: /s/ Patrick Smerkers, Senior Vice President, Finance and Operations	09/14/2021
	Northpond Ventures, LP By: Northpond Ventures GP, LLC, its general partner By: /s/ Patrick Smerkers, Senior Vice President, Finance and Operations	09/14/2021
	Northpond Ventures GP II, LLC By: /s/ Patrick Smerkers, Senior Vice President, Finance and Operations	09/14/2021
	Northpond Ventures II, LP By: Northpond Ventures GP II, LLC, its general partner By: /s/ Patrick Smerkers, Senior Vice President, Finance and Operations	09/14/2021
	/s/ Michael P. Rubin	09/14/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Northpond Ventures Form 3DICE Therapeutics / Michael P. Rubin ownership change